isabelobrien, Author at European Medical Journal - Page 8 of 29

Europe's biopharma SMEs need urgent support, warns EFPIA

Europe must act urgently to back small and medium-sized enterprises (SMEs) in the biopharmaceutical sector, says the EFPIA.

Handshake on blue background

FDA greenlights UCB’s IL-17 inhibitor for HS

The novel IL-17A and IL-17F inhibitor has been approved the treatment of moderate to severe hidradenitis suppurativa, a chronic and painful skin disease.

Building a high performance customer experience model

In the pharmaceutical industry, improving customer experience has become the goal, but it’s time to look at it in a new way.

Revisto raises $4m to streamline pharma compliance with AI

Revisto has raised $4m in seed funding to simplify the pharmaceutical industry’s marketing compliance processes using AI.

5 minutes with… Roxana Redis, Charles River Laboratories

Roxana Redis, Associate Science Director of Advanced Modalities, Charles River Laboratories, talks about the exciting field of RNA.

Europe’s pharma R&D productivity grows, but falls behind US and China

Europe’s pharmaceutical research and development sector is in a tight spot as new data reveals that R&D spending isn’t keeping up with global competitors.

Red arrow tracking bar chart that is ascending in height

BMS, Gilead and Sanofi lead Q3 2024 market cap growth

The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players, according to GlobalData.

FDA nod for Johnson & Johnson’s atrial fibrillation device

Johnson & Johnson MedTech has received FDA approval for its device for drug-refractory paroxysmal atrial fibrillation.

AZ's new obesity pill shows promise, enters phase II

AstraZeneca’s new weight-loss pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

The word spotlight on a blue background with the 'o' as a spotlight circle

Spotlight: October 2024

Catch up on all the biggest news to hit the pharmaceutical industry last month, spanning from new acquisitions, approvals, insights on the NHS and more.